COVID-19 and immunomodulation treatment for women with reproductive failures
Document Type
Article
Publication Date
9-1-2020
Publication Title
Journal of reproductive immunology
Abstract
© 2020 Elsevier B.V. COVID-19 pandemic is affecting various areas of health care, including human reproduction. Many women with reproductive failures, during the peri-implantation period and pregnancy, are on the immunotherapy using immune modulators and immunosuppressant due to underlying autoimmune diseases, cellular immune dysfunction, and rheumatic conditions. Many questions have been raised for women with immunotherapy during the COVID-19 pandemic, including infection susceptibility, how to manage women with an increased risk of and active COVID-19 infection. SARS-CoV-2 is a novel virus, and not enough information exists. Yet, we aim to review the data from previous coronavirus outbreaks and current COVID-19 and provide interim guidelines for immunotherapy in women with reproductive failures.
Volume
141
First Page
103168
Recommended Citation
Kwak-Kim J, Ota K, Sung N, Huang C, Alsubki L, Lee S, Han JW, Han A, Yang X, Saab W, Derbala Y, Wang WJ, He Q, Liao A, Takahashi T, Cavalcante MB, Barini R, Bao S, Fukui A, Lédée N, Coulam C. COVID-19 and immunomodulation treatment for women with reproductive failures. J Reprod Immunol. 2020 Sep;141:103168. doi: 10.1016/j.jri.2020.103168. Epub 2020 Jun 12. PMID: 32603991; PMCID: PMC7291967.
DOI
10.1016/j.jri.2020.103168
ISSN
1872-7603
PubMed ID
32603991